Physician profile
Eric H Chan
NPI 1427443316
$4,637.24
in general payments reported to CMS, 2019-2025
19 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $543 · 2021: $717 · 2022: $453 · 2023: $1,983 · 2024: $200 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,380 · Food and Beverage: $919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,380.00 |
| Food and Beverage | $919.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,637.11 | 2020-2023 | Iaccess Precision Blade |
| Ivantis, INC | $586.26 | 2019-2021 | |
| Alcon Vision LLC | $336.11 | 2019-2025 | Rocklatan, Tryptyr |
| Abbvie INC. | $324.05 | 2023-2025 | Xen Glaucoma Treatment System, Alphagan P, Lumigan |
| Sight Sciences, INC. | $316.12 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| New World Medical,INC. | $274.36 | 2021-2025 | Via360, Clearpath, Streamline |
| Allergan, INC. | $211.81 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $169.45 | 2020-2021 | |
| Regeneron Pharmaceuticals, INC. | $130.40 | 2019 | |
| Dompe US, INC. | $125.00 | 2021 | |
| Kala Pharmaceuticals, INC. | $125.00 | 2021 | |
| Shire North American Group INC | $111.54 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $88.77 | 2022-2023 | Tecnis Iol |
| Viiv Healthcare Company | $83.25 | 2024 | Dovato, Cabenuva |
| Bausch & Lomb Americas INC. | $37.07 | 2024-2025 | Miebo, Xiidra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $24.93 | 2023 | Remodulin |
| Rxsight INC | $24.37 | 2023 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
| Sun Pharmaceutical Industries INC. | $19.00 | 2023 | Cequa |
| Horizon Therapeutics Plc | $12.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.